Navigating the brain: Harnessing endogenous cellular hitchhiking for targeting neoplastic and neuroinflammatory diseases

Abstract

Cellular hitchhiking is an emerging therapeutic strategy that uses an endogenous cell migration mechanism to deliver therapeutics to specific sites in the body. Owing to the low permeability and presence of the blood-brain barrier (BBB), the targeted delivery of therapeutics is limited, leading to inadequate localization in the brain. NCs fail to extravasate significantly into the tumor microenvironment (TME), demonstrating poor accumulation and tumor penetration. The novel cellular hitchhiking concept has been utilized to promote systemic half-life and therapeutic targeting. Neoplastic and neuroinflammatory diseases of the brain, including glioblastoma and neuroinflammation, face critical hurdles for efficiently delivering therapeutic entities owing to the BBB. Cellular hitchhiking can surmount these hurdles by utilizing various cell populations, such as stem cells, monocytes/macrophages, neutrophils, and platelets, as potential functional carriers to deliver the therapeutic cargo through the BBB. These carrier cells have the innate capability to traverse the BBB, transit through the brain parenchyma, and specifically reach disease sites such as inflammatory and neoplastic lesions owing to chemotactic navigation, i.e., movement attributed to chemical stimuli. Chemotherapeutic drugs delivered by cellular hitchhiking to achieve tumor-specific targeting have been discussed. This article explores various cell types for hitchhiking NCs to the TME with in-depth mechanisms and characterization techniques to decipher the backpack dissociation dynamics (nanoparticle payload detachment characteristics from hitchhiked cells) and challenges toward prospective clinical translation.

Keywords

Cellular hitchhiking / Glioblastoma / Brain-targeting

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Acknowledgments

The authors would like to acknowledge the research funding support by the Department of Pharmaceuticals (DoP), Ministry of Chemicals and Fertilizers, Govt. of India to "Pharmaceutical Innovation and Translational Research Lab" (PITRL), Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) Hyderabad, INDIA.

References

[1] Liu Q, Li X, Wang Y, Liu X, Cao Y, Zhang H, et al. Neutrophil hitchhiking for nanoparticle delivery to the central nervous system. Appl Mater Today 2024; 38:102259.

[2] Liu X, Yin L, Shen S, Hou Y. Inflammation and cancer: paradoxical roles in tumorigenesis and implications in immunotherapies. Genes Dis 2023; 10:151-64.

[3] Patterson CM, Shaw TD, Gerovasili V, Khatana U, Jose RJ. Emerging therapies and respiratory infections: focus on the impact of immunosuppressants and immunotherapies. Clinical Medicine 2024; 24:100015.

[4] Kaur N, Chugh H, Sakharkar MK, Dhawan U, Chidambaram SB, Chandra R. Neuroinflammation mechanisms and phytotherapeutic intervention: a systematic review. ACS Chem Neurosci 2020; 11:3707-31.

[5] Euteneuer F, Dannehl K, del Rey A, Engler H, Schedlowski M, Rief W. Immunological effects of behavioral activation with exercise in major depression: an exploratory randomized controlled trial. Transl Psychiatry 2017; 7:e1132.

[6] Yuste JE, Tarragon E, Campuzano CM. Ros-Bernal F. Implications of glial nitric oxide in neurodegenerative diseases. Front Cell Neurosci 2015; 9:322.

[7] Miranda A, Blanco-Prieto MJ, Sousa J, Pais A, Vitorino C. Breaching barriers in glioblastoma. Part II: targeted drug delivery and lipid nanoparticles. Int J Pharm 2017; 531:389-410.

[8] Sikder A, Pasupuleti V, Khairnar P, Phatale V, Amulya E, Wagh SS, et al. Deciphering convection enhanced delivery: a paradigm shift for circumventing glioblastoma multiforme. J Drug Deliv Sci Technol 2025; 103:106398.

[9] Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res 2021; 171:105780.

[10] Sesé B, Ensenyat-Mendez M, Iñiguez S, Llinàs-Arias P, Marzese DM. Chromatin insulation dynamics in glioblastoma: challenges and future perspectives of precision oncology. Clin Epigenetics 2021; 13:150.

[11] Branco F, Cunha J, Mendes M, Vitorino C, Sousa JJ. Peptide-hitchhiking for the development of nanosystems in glioblastoma. ACS Nano 2024; 18:16359-94.

[12] Sales A, Beck J, Schnell O, Fung C, Meyer B, Gempt J. Surgical treatment of glioblastoma: state-of-the-art and future trends. J Clin Med 2022; 11:5354.

[13] Achar A, Myers R, Ghosh C. Drug delivery challenges in brain disorders across the blood-brain barrier: novel methods and future considerations for improved therapy. Biomedicines 2021; 9:1834.

[14] Bhunia S, Kolishetti N, Vashist A, Yndart AA, Brooks D, Nair M. Drug delivery to the brain: recent advances and unmet challenges. Pharmaceutics 2023; 15:2658.

[15] Xu Y, Wei L, Wang H. Progress and perspectives on nanoplatforms for drug delivery to the brain. J Drug Deliv Sci Technol 2020; 57:101636.

[16] Ansari A, Hussain A, Wadekar R, Altamimi MA, Malik A, Mujtaba MA, et al. Nanovesicles based drug targeting to control tumor growth and metastasis. Adv Cancer Biol Metastasis 2023; 7:100083.

[17] Park J, Hsueh P-C, Li Z, Ho PC. Microenvironment-driven metabolic adaptations guiding CD8+ T cell anti-tumor immunity. Immunity 2023; 56:32-42.

[18] Fang LR, Wang YH, Xiong ZZ, Wang Y-M. Research progress of nanomaterials in tumor-targeted drug delivery and imaging therapy. OpenNano 2023; 14:100184.

[19] Ding Y, Pan Q, Gao W, Pu Y, Luo K, He B. Reactive oxygen species-upregulating nanomedicines towards enhanced cancer therapy. Biomater Sci 2023; 11:1182-214.

[20] Batool S, Sohail S, ud Din F, Alamri AH, Alqahtani AS, Alshahrani MA, et al. A detailed insight of the tumor targeting using nanocarrier drug delivery system. Drug Deliv 2023; 30(1):2183815.

[21] Huang X, Wang L, Guo H, Zhang W. Macrophage membrane-coated nanovesicles for dual-targeted drug delivery to inhibit tumor and induce macrophage polarization. Bioact Mater 2023; 23:69-79.

[22] Wagh SS, Sarolia J, Patil YK, Aswal VK, Bahadur P, Tiwari S. Cooperative interaction of a highly hydrophilic pluronic with bile salts of different hydrophobicity. Colloids Surf A Physicochem Eng Asp 2023; 672:131709.

[23] Bourquin J, Milosevic A, Hauser D, Lehner R, Blank F, Petri-Fink A, et al. Biodistribution, clearance, and long-term fate of clinically relevant nanomaterials. Advanced Materials 2018; 30(19):1704307.

[24] Anvari Lytle, Walker Gupta, Vullev Anvari. Effects of nanoencapsulation and PEGylation on biodistribution of indocyanine green in healthy mice: quantitative fluorescence imaging and analysis of organs. Int J Nanomedicine 2013; 8:1609.

[25] Zhu GH, Azharuddin M, Islam R, Rahmoune H, Deb S, Kanji U, et al. Innate immune invisible ultrasmall gold nanoparticles-framework for synthesis and evaluation. ACS Appl Mater Interfaces 2021; 13:23410-22.

[26] Jain N, Shahrukh S, Famta P, Shah S, Vambhurkar G, Khatri DK, et al. Immune cell-camouflaged surface-engineered nanotherapeutics for cancer management. Acta Biomater 2023; 155:57-79.

[27] Duggan ST, Keating GM. Pegylated liposomal doxorubicin. Drugs 2011; 71:2531-58.

[28] Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev 2020;154-155:163-75.

[29] Eftekhari A, Kryschi C, Pamies D, Gulec S, Ahmadian E, Janas D, et al. Natural and synthetic nanovectors for cancer therapy. Nanotheranostics 2023; 7:236-57.

[30] Famta P, Shah S, Vambhurkar G, Pandey G, Bagasariya D, Kumar KC, et al. Amelioration of breast cancer therapies through normalization of tumor vessels and microenvironment: paradigm shift to improve drug perfusion and nanocarrier permeation. Drug Deliv Transl Res 2025; 15:389-406.

[31] Beh CY, Prajnamitra RP, Chen LL, Hsieh PCH. Advances in biomimetic nanoparticles for targeted cancer therapy and diagnosis. Molecules 2021; 26:5052.

[32] Dai Q, Wilhelm S, Ding D, Syed AM, Sindhwani S, Zhang Y, et al. Quantifying the ligand-coated nanoparticle delivery to cancer cells in solid tumors. ACS Nano 2018; 12:8423-35.

[33] Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021; 20:101-24.

[34] Shah S, Famta P, Vambhurkar G, Kumar R, Pandey G, Singh G, et al. Docetaxel and niclosamide-loaded nanofiber systems for improved chemo-therapeutic activity and resistance reversal in prostate cancer. Drug Dev Ind Pharm 2025; 51:132-43.

[35] Shah S, Famta P, Kumar R, Vambhurkar G, Pandey G, Shinde A, et al. QbD manoeuvred niclosamide laden polylactic-co-glycolic acid nanoparticles-impregnated gelatin nanofibers for the management of oral carcinoma. Bionanoscience 2025; 15:221.

[36] Huang WC, Lu IL, Chiang WH, Lin YW, Tsai YC, Chen HH, et al. Tumortropic adipose-derived stem cells carrying smart nanotherapeutics for targeted delivery and dual-modality therapy of orthotopic glioblastoma. J Controlled Rel 2017; 254:119-30.

[37] Mo R, Gu Z. Tumor microenvironment and intracellular signal-activated nanomaterials for anticancer drug delivery. Mater Today 2016; 19:274-83.

[38] Anselmo AC, Kumar S, Gupta V, Pearce AM, Ragusa A, Muzykantov V, et al. Exploiting shape, cellular-hitchhiking and antibodies to target nanoparticles to lung endothelium: synergy between physical, chemical and biological approaches. Biomaterials 2015; 68:1-8.

[39] Udofa E, Zhao Z. In situ cellular hitchhiking of nanoparticles for drug delivery. Adv Drug Deliv Rev 2024; 204:115143.

[40] Pan Y, Cheng J, Zhu Y, Zhang J, Fan W, Chen X. Immunological nanomaterials to combat cancer metastasis. Chem Soc Rev 2024; 53:6399-444.

[41] Wang Y, Sun S-K, Liu Y, Zhang Z. Advanced hitchhiking nanomaterials for biomedical applications. Theranostics 2023; 13:4781-801.

[42] Kuang J, Rao ZY, Zheng DW, Kuang D, Huang QX, Pan T, et al. Nanoparticles hitchhike on monocytes for glioblastoma treatment after low-dose radiotherapy. ACS Nano 2023; 17:13333-47.

[43] Mu Q, Yao K, Syeda MZ, Zhang M, Cheng Q, Zhang Y, et al. Ligustrazine nanoparticle hitchhiking on neutrophils for enhanced therapy of cerebral ischemia-reperfusion injury. Adv Sci 2023; 10:2301348.

[44] Anselmo AC, Gupta V, Zern BJ, Pan D, Zakrewsky M, Muzykantov V, et al. Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells. ACS Nano 2013; 7:11129-37.

[45] Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer 2017; 17:20-37.

[46] Yan H, Shao D, Lao Y, Li M, Hu H, Leong KW. Engineering cell membrane-based nanotherapeutics to target inflammation. Adv Sci 2019; 6(15):1900605.

[47] Fenn AM, Gensel JC, Huang Y, Popovich PG, Lifshitz J, Godbout JP. Immune activation promotes depression 1 month after diffuse brain injury: A role for primed microglia. Biol Psychiatry 2014; 76:575-84.

[48] Franco R, Fernández-Suárez D. Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol 2015; 131:65-86.

[49] Yang I, Han SJ, Kaur G, Crane C, Parsa AT. The role of microglia in central nervous system immunity and glioma immunology. J Clin Neurosci 2010; 17:6-10.

[50] Lehnardt S. Innate immunity and neuroinflammation in the CNS: the role of microglia in toll-like receptor-mediated neuronal injury. Glia 2010; 58:253-63.

[51] Harry GJ, Kraft AD. Neuroinflammation and microglia: considerations and approaches for neurotoxicity assessment. Expert Opin Drug Metab Toxicol 2008; 4:1265-77.

[52] Klyachko NL, Polak R, Haney MJ, Zhao Y, Gomes Neto RJ, Hill MC, et al. Macrophages with cellular backpacks for targeted drug delivery to the brain. Biomaterials 2017; 140:79-87.

[53] Li X, Geng X, Chen Z, Yuan Z. Recent advances in glioma microenvironment-response nanoplatforms for phototherapy and sonotherapy. Pharmacol Res 2022; 179:106218.

[54] Kim HS, Seo M, Park TE, Lee DY. A novel therapeutic strategy of multimodal nanoconjugates for state-of-the-art brain tumor phototherapy. J Nanobiotechnology 2022; 20:14.

[55] Zhu Y, Niu X, Ding C, Lin Y, Fang W, Yan L, et al. Carrier-free self-assembly nano-sonosensitizers for sonodynamic-amplified cuproptosis-ferroptosis in glioblastoma therapy. Advanced Science 2024; 11(23):2402516.

[56] Zhu Y, Ding C, Fang W, Li T, Yan L, Tian Y, et al. Metal-polyphenol self-assembled nanodots for NIR-II fluorescence imaging-guided chemodynamic/photodynamic therapy-amplified ferroptosis. Acta Biomater 2024; 185:361-70.

[57] Lan T, Chen L, Wei X. Inflammatory cytokines in cancer: comprehensive understanding and clinical progress in gene therapy. Cells 2021; 10:100.

[58] Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 2017; 17:559-72.

[59] Henneken M, Dörner T, Burmester G-R, Berek C. Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2005;7:R1001.

[60] Hattermann K, Held-Feindt J, Lucius R, Müerköster SS, Penfold MET, Schall TJ, et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res 2010; 70:3299-308.

[61] Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454:436-44.

[62] Shi C, Pamer EG. Monocyte recruitment during infection and inflammation. Nat Rev Immunol 2011; 11:762-74.

[63] Henze AT, Mazzone M. The impact of hypoxia on tumor-associated macrophages. J Clin Investigat 2016; 126:3672-9.

[64] Su Y, Xie Z, Kim GB, Dong C, Yang J. Design strategies and applications of circulating cell-mediated drug delivery systems. ACS Biomater Sci Eng 2015; 1:201-17.

[65] Batrakova EV, Gendelman HE, Kabanov AV. Cell-mediated drug delivery. Expert Opin Drug Deliv 2011; 8:415-33.

[66] Anselmo AC, Mitragotri S. Cell-mediated delivery of nanoparticles: taking advantage of circulatory cells to target nanoparticles. J Controll Rel 2014; 190:531-41.

[67] Cuesta-Gomez N, Graham GJ, Campbell JDM. Chemokines and their receptors: predictors of the therapeutic potential of mesenchymal stromal cells. J Transl Med 2021; 19:156.

[68] Litvinova LS, Shupletsova VV, Khaziakhmatova OG, Daminova AG, Kudryavtseva VL, Yurova KA, et al. Human mesenchymal stem cells as a carrier for a cell-mediated drug delivery. Front Bioeng Biotechnol 2022; 10:796111.

[69] Yousefpour P, Chilkoti A. Co-opting biology to deliver drugs. Biotechnol Bioeng 2014; 111:1699-716.

[70] Xu XR, Yousef GM, Ni H. Cancer and platelet crosstalk: opportunities and challenges for aspirin and other antiplatelet agents. Blood 2018; 131:1777-89.

[71] Plantureux L, Mège D, Crescence L, Carminita E, Robert S, Cointe S, et al. The interaction of platelets with colorectal cancer cells inhibits tumor growth but promotes metastasis. Cancer Res 2020; 80:291-303.

[72] Labelle M, Begum S, Hynes RO. Platelets guide the formation of early metastatic niches. Proceed Natl Acad Sci 2014; 111(30):E3053-61.

[73] Chen WW, Zhang X, Huang WJ. Role of neuroinflammation in neurodegenerative diseases (Review). Mol Med Rep 2016; 13:3391-6.

[74] Ní Chasaide C, Lynch MA. The role of the immune system in driving neuroinflammation. Brain Neurosci Adv 2020; 4:2398212819901082.

[75] Benakis C, Martin-Gallausiaux C, Trezzi JP, Melton P, Liesz A, Wilmes P. The microbiome-gut-brain axis in acute and chronic brain diseases. Curr Opin Neurobiol 2020; 61:1-9.

[76] Rossi S, Studer V, Motta C, Polidoro S, Perugini J, Macchiarulo G, et al. Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis. Neurology 2017; 89:1338-47.

[77] Marchetti L, Engelhardt B. Immune cell trafficking across the blood-brain barrier in the absence and presence of neuroinflammation. Vasc Biol 2020;2:H1-18.

[78] Troubat R, Barone P, Leman S, Desmidt T, Cressant A, Atanasova B, et al. Neuroinflammation and depression: a review. Eur J Neurosci 2021; 53:151-71.

[79] Hsieh JT, St John AL. Japanese encephalitis virus and its mechanisms of neuroinvasion. PLoS Pathog 2020; 16:e1008260.

[80] Paolilo RB, Deiva K, Neuteboom R, Rostásy K, Lim M. Acute disseminated encephalomyelitis: current perspectives. Children 2020; 7:210.

[81] Bauer ME, Teixeira AL. Neuroinflammation in mood disorders: role of regulatory immune cells. Neuroimmunomodulation 2021; 28:99-107.

[82] Mozafari N, Ashrafi H, Azadi A. Targeted drug delivery systems to control neuroinflammation in central nervous system disorders. J Drug Deliv Sci Technol 2021; 66:102802.

[83] Dymova MA, Kuligina EV, Richter VA. Molecular mechanisms of drug resistance in glioblastoma. Int J Mol Sci 2021; 22:6385.

[84] Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, et al. Glioma. Nat Rev Dis Primers 2024; 10:33.

[85] Hu F a Dzaye OD, Hahn A, Yu Y, Scavetta RJ, Dittmar G, et al. Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages toll-like receptor 2 signaling. Neuro Oncol 2015; 17:200-10.

[86] Ippen FM, Grosch JK, Subramanian M, Kuter BM, Liederer BM, Plise EG, et al. Targeting the PI3K/akt/mTOR pathway with the pan-akt inhibitor GDC-0068 in PIK3CA-mutant breast cancer brain metastases. Neuro Oncol 2019; 21:1401-11.

[87] Guo G, Yao W, Zhang Q, Bo Y. Oleanolic acid suppresses migration and invasion of malignant glioma cells by inactivating MAPK/ERK signaling pathway. PLoS One 2013; 8:e72079.

[88] Huang B, Abraham WD, Zheng Y, Bustamante López SC, Luo SS, Irvine DJ. Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells. Sci Transl Med 2015;7.

[89] Sofias AM, Toner YC, Meerwaldt AE, van Leent MMT, Soultanidis G, Elschot M, et al. Tumor targeting by av$\beta$3 -integrin-specific lipid nanoparticles occurs via phagocyte hitchhiking. ACS Nano 2020; 14:7832-46.

[90] Mehta P, Shende P. Evasion of opsonization of macromolecules using novel surface-modification and biological-camouflage-mediated techniques for next-generation drug delivery. Cell Biochem Funct 2023; 41:1031-43.

[91] Abd Ellah NH, Abouelmagd SA. Surface functionalization of polymeric nanoparticles for tumor drug delivery: approaches and challenges. Expert Opin Drug Deliv 2017; 14:201-14.

[92] Malachowski T, Hassel A. Engineering nanoparticles to overcome immunological barriers for enhanced drug delivery. Engine Regener 2020; 1:35-50.

[93] Toy R, Roy K. Engineering nanoparticles to overcome barriers to immunotherapy. Bioeng Transl Med 2016; 1:47-62.

[94] Khatoon N, Zhang Z, Zhou C, Chu M. Macrophage membrane coated nanoparticles: a biomimetic approach for enhanced and targeted delivery. Biomater Sci 2022; 10:1193-208.

[95] Qie Y, Yuan H, von Roemeling CA, Chen Y, Liu X, Shih KD, et al. Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes. Sci Rep 2016; 6:26269.

[96] Kim Y-H, Min KH, Wang Z, Kim J, Jacobson O, Huang P, et al. Development of sialic acid-coated nanoparticles for targeting cancer and efficient evasion of the immune system. Theranostics 2017; 7:962-73.

[97] Li M, Zhang F, Chen K, Wang C, Su Y, Liu Y, et al. Nanoparticles and mesenchymal stem cells: a win-win alliance for anticancer drug delivery. RSC Adv 2016; 6:36910-22.

[98] Wang S, Han K, Ma S, Qi X, Guo L, Li X. Blood cells as supercarrier systems for advanced drug delivery. Med Drug Discov 2022; 13:100119.

[99] Das R, Hardie J, Joshi BP, Zhang X, Gupta A, Luther DC, et al. Macrophage-encapsulated bioorthogonal nanozymes for targeting cancer cells. JACS Au 2022; 2:1679-85.

[100] Li J, Cheng Q Yue L, Gao C, Wei J, Ding Y, et al. Macrophage-hitchhiking supramolecular aggregates of CuS nanoparticles for enhanced tumor deposition and photothermal therapy. Nanoscale Horiz 2021; 6:907-12.

[101] Torrieri G, Iqbal I, Fontana F, Talman V, Liljenbäck H, Putri A, et al. Macrophage hitchhiking nanoparticles for the treatment of myocardial infarction: an in vitro and in vivo study. Adv Funct Mater 2023; 33(34):2303658.

[102] Kelly C, Jefferies C, Cryan SA. Targeted liposomal drug delivery to monocytes and macrophages. J Drug Deliv 2011; 2011:1-11.

[103] Choi J, Kim HY, Ju EJ, Jung J, Park J, Chung HK, et al. Use of macrophages to deliver therapeutic and imaging contrast agents to tumors. Biomaterials 2012; 33:4195-203.

[104] Sarma A, Das MK. Nose to brain delivery of antiretroviral drugs in the treatment of neuroAIDS. Molec Biomed 2020; 1:1-23.

[105] Gong Y, Chowdhury P, Nagesh PKB, Rahman MA, Zhi K, Yallapu MM, et al. Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages. Sci Rep 2020; 10:1-16.

[106] Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, et al. Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immuno 2009; 183:661-9.

[107] Liu H, Han Y, Wang T, Zhang H, Xu Q, Yuan J, et al. Targeting microglia for therapy of parkinson's disease by using biomimetic ultrasmall nanoparticles. J Am Chem Soc 2020; 142:21730-42.

[108] Zhao Y, Haney MJ, Fallon JK, Rodriguez M, Swain CJ, Arzt CJ, et al. Using extracellular vesicles released by GDNF-transfected macrophages for therapy of parkinson disease. Cells 2022; 11:1933.

[109] Pang L, Zhu Y, Qin J, Zhao W, Wang J. Primary M1 macrophages as multifunctional carrier combined with PLGA nanoparticle delivering anticancer drug for efficient glioma therapy. Drug Deliv 2018; 25:1922-31.

[110] He X, Cao H, Wang H, Tan T, Yu H, Zhang P, et al. Inflammatory monocytes loading protease-sensitive nanoparticles enable lung metastasis targeting and intelligent drug release for anti-metastasis therapy. Nano Lett 2017; 17:5546-54.

[111] Nguyen PHD, Jayasinghe MK, Le AH, Peng B, Le MTN. Advances in drug delivery systems based on red blood cells and their membrane-derived nanoparticles. ACS Nano 2023; 17:5187-210.

[112] Zhan Q, Yi K, Cui X, Li X, Yang S, Wang Q et al. Blood exosomes-based targeted delivery of CPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy. Neuro Oncol 2022; 24:1871-83.

[113] Liu X, Yi X, Gu J, Ji Z, Zhu M, Shen M, et al. Immunoregulatory liposomes hitchhiking on neutrophils for enhanced carbon ion radiotherapy-assisted immunotherapy of glioblastoma. Nano Today 2023; 53:102037.

[114] Lenders V, Escudero R, Koutsoumpou X, Armengol Álvarez L, Rozenski J, Soenen SJ, et al. Modularity of RBC hitchhiking with polymeric nanoparticles: testing the limits of non-covalent adsorption. J Nanobiotechnol 2022; 20:333.

[115] Chambers E, Mitragotri S. Prolonged circulation of large polymeric nanoparticles by non-covalent adsorption on erythrocytes. J Controlled Rel 2004; 100:111-9.

[116] Dai Q, Yan Y, Ang CS, Kempe K, Kamphuis MMJ, Dodds SJ, et al. Monoclonal antibody-functionalized multilayered particles: targeting cancer cells in the presence of protein coronas. ACS Nano 2015; 9:2876-85.

[117] Goodwin PC. Quantitative deconvolution microscopy. Methods Cell Biol 2014; 123:177-92.

[118] Yang L, Yang Y, Chen Y, Xu Y, Peng J. Cell-based drug delivery systems and their in vivo fate. Adv Drug Deliv Rev 2022; 187:114394.

[119] Malinowski P, Skała K, Jabłońska-Trypuć A, Koronkiewicz A, Wołejko E, Wydro U, et al.Comparison of the usefulness of MTT and CellTiterGlo tests applied for cytotoxicity evaluation of compounds from the group of polyphenols. Environment Sci Proceedings 2022; 18(1):9.

[120] Pan DC, Myerson JW, Brenner JS, Patel PN, Anselmo AC, Mitragotri S, et al. Nanoparticle properties modulate their attachment and effect on carrier red blood cells. Sci Rep 2018; 8:1615.

[121] Nikfar M, Razizadeh M, Paul R, Muzykantov V, Liu Y. A numerical study on drug delivery via multiscale synergy of cellular hitchhiking onto red blood cells. Nanoscale 2021; 13:17359-72.

[122] Tan J, Thomas A, Liu Y. Influence of red blood cells on nanoparticle targeted delivery in microcirculation. Soft Matter 2012; 8:1934-46.

[123] Müller K, Fedosov DA, Gompper G. Margination of micro- and nano-particles in blood flow and its effect on drug delivery. Sci Rep 2014; 4:4871.

[124] Salogiannis J, Egan MJ, Reck-Peterson SL. Peroxisomes move by hitchhiking on early endosomes using the novel linker protein PxdA. J Cell Biol 2016; 212:289-96.

[125] Wiwatchaitawee K, Ebeid K, Quarterman JC, Naguib Y, Ali MY, Oliva C, et al. Surface modification of nanoparticles enhances drug delivery to the brain and improves survival in a glioblastoma multiforme murine model. Bioconjug Chem 2022; 33:1957-72.

[126] Liu T, Gao C, Gu D, Tang H. Cell-based carrier for targeted hitchhiking delivery. Drug Deliv Transl Res 2022; 12:2634-48.

[127] Mangraviti A, Gullotti D, Tyler B, Brem H. Nanobiotechnology-based delivery strategies: new frontiers in brain tumor targeted therapies. J Controlled Rel 2016; 240:443-53.

[128] Buonfiglioli A, Hambardzumyan D. Macrophages and microglia: the cerberus of glioblastoma. Acta Neuropathol Commun 2021; 9:54.

[129] Pombo Antunes AR, Scheyltjens I, Lodi F, Messiaen J, Antoranz A, Duerinck J, et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat Neurosci 2021; 24:595-610.

[130] Tomaszewski W, Sanchez-Perez L, Gajewski TF, Sampson JH. Brain tumor microenvironment and host state: implications for immunotherapy. Clin Cancer Res 2019; 25:4202-10.

[131] Aretz P, Maciaczyk D, Yusuf S, Sorg RV, Hänggi D, Liu H, et al. Crosstalk between $\beta$-catenin and CCL 2 drives migration of monocytes towards glioblastoma cells. Int J Mol Sci 2022; 23:4562.

[132] Gschwandtner M, Derler R, Midwood KS. More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis. Front Immunol 2019; 10:2759.

[133] Mondini M, Loyher P-L, Hamon P, Gerbé de Thoré M, Laviron M, Berthelot K, et al. CCR2-dependent recruitment of tregs and monocytes following radiotherapy is associated with TNF a-mediated resistance. Cancer Immunol Res 2019; 7:376-87.

[134] Argyle D, Kitamura T. Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors. Front Immunol 2018; 9:2629.

[135] Wróblewska A, Szczygieł A, Szermer-Olearnik B, Pajtasz-Piasecka E. Macrophages as promising carriers for nanoparticle delivery in anticancer therapy. Int J Nanomedicine 2023; 18:4521-39.

[136] Wang S, Shen H, Mao Q, Tao Q, Yuan G, Zeng L, et al. Macrophage-mediated porous magnetic nanoparticles for multimodal imaging and postoperative photothermal therapy of gliomas. ACS Appl Mater Interfaces 2021; 13:56825-37.

[137] Owen JL, Mohamadzadeh M. Macrophages and chemokines as mediators of angiogenesis. Front Physiol 2013;4(JUL):55043.

[138] Pei Y, Yeo Y. Drug delivery to macrophages: challenges and opportunities. J Controlled Rel 2016; 240:202-11.

[139] Kroner A, Greenhalgh AD, Zarruk JG, Passos dos R, Gaestel M, David S. TNF and increased intracellular iron alter macrophage polarization to a detrimental M1 phenotype in the injured spinal cord. Neuron 2014; 83:1098-116.

[140] Papa S, Ferrari R, De Paola M, Rossi F, Mariani A, Caron I, et al. Polymeric nanoparticle system to target activated microglia/macrophages in spinal cord injury. J Controlled Rel 2014; 174:15-26.

[141] Martinez FO, Gordon S.The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014; 6:13.

[142] Lasek W, Zagozdzon R, Marek J.Interleukin 12:antitumor activity and immunotherapeutic potential in oncology, 1; 2016. p. 1-43. doi:10.1007/978-3-319-46906-5.

[143] Pang L, Qin J, Han L, Zhao W, Liang J, Xie Z, et al. Exploiting macrophages as targeted carrier to guide nanoparticles into glioma. Oncotarget 2016; 7:37081-91.

[144] Biserova K, Jakovlevs A, Uljanovs R, Strumfa I. Cancer stem cells: significance in origin, pathogenesis and treatment of glioblastoma. Cells 2021; 10:621.

[145] Bowman RL, Klemm F, Akkari L, Pyonteck SM, Sevenich L, Quail DF, et al. Macrophage ontogeny underlies differences in tumor-specific education in brain malignancies. Cell Rep 2016; 17:2445-59.

[146] Zhang R, Ye Y, Wu J, Gao J, Huang W, Qin H, et al. Immunostimulant in situ fibrin gel for post-operative glioblastoma treatment by macrophage reprogramming and photo-chemo-immunotherapy. ACS Appl Mater Interfaces 2023; 15:17627-40.

[147] Quintero-Fabián S, Arreola R, Becerril-Villanueva E, Torres-Romero JC, Arana-Argáez V, Lara-Riegos J, et al. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol 2019; 9:1370.

[148] Feng Y, Zhu M, Dangelmajer S, Lee YM, Wijesekera O, Castellanos CX, et al. Hypoxia-cultured human adipose-derived mesenchymal stem cells are non-oncogenic and have enhanced viability, motility, and tropism to brain cancer. Cell Death Dis 2014; 5:e1567.

[149] Pendleton C, Li Q, Chesler DA, Yuan K, Guerrero-Cazares H, Quinones-Hinojosa A. Mesenchymal stem cells derived from adipose tissue us bone marrow: In vitro comparison of their tropism towards gliomas. PLoS One 2013; 8:e58198.

[150] Josiah DT, Zhu D, Dreher F, Olson J, McFadden G, Caldas H. Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma. Molecular Ther 2010; 18:377-85.

[151] Choi SA, Lee JY, Kwon SE, Wang K-C, Phi JH, Choi JW, et al. Human adipose tissue-derived mesenchymal stem cells target brain tumor-initiating cells. PLoS One 2015; 10(6):e0129292.

[152] Sarin H, Kanevsky AS, Wu H, Brimacombe KR, Fung SH, Sousa AA, et al. Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med 2008; 6:80.

[153] Laquintana V, Trapani A, Denora N, Wang F, Gallo JM, Trapani G. New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv 2009; 6:1017-32.

[154] Sun C, Wang S, Ma Z, Zhou J, Ding Z, Yuan G, et al. Neutrophils in glioma microenvironment: from immune function to immunotherapy. Front Immunol 2024; 15:1393173.

[155] Lin YJ, Wei KC, Chen PY, Lim M, Hwang TL. Roles of neutrophils in glioma and brain metastases. Front Immunol 2021; 12:701383.

[156] Wu M, Zhang H, Tie C, Yan C, Deng Z, Wan Q et al. MR imaging tracking of inflammation-activatable engineered neutrophils for targeted therapy of surgically treated glioma. Nat Commun 2018; 9:4777.

[157] Wallin MT, Culpepper WJ, Campbell JD, Nelson LM, Langer-Gould A, Ann Marrie R, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology 2019; 92(10):e1029-40.

[158] Zhao F, Zhao Y, Liu Y, Chang X, Chen C, Zhao Y. Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. Small 2011; 7:1322-37.

[159] Xu Y, Yang C, Wu Y, Jiang W, Cheng Q, Yan L, et al. In situ albumin-hitchhiking NIR-II probes for accurate detection of micrometastases. Nano Lett 2023; 23:5731-7.

[160] Kapate N, Dunne M, Kumbhojkar N, Prakash S, Wang LLW, Graveline A, et al. A backpack-based myeloid cell therapy for multiple sclerosis. Proceed Natl Acad Sci 2023; 120(17):e2221535120.

[161] Lu L, Qi S, Chen Y, Luo H, Huang S, Yu X, et al. Targeted immunomodulation of inflammatory monocytes across the blood-brain barrier by curcumin-loaded nanoparticles delays the progression of experimental autoimmune encephalomyelitis. Biomaterials 2020; 245:119987.

[162] Hao J, Chen J, Wang M, Zhao J, Wang J, Wang X, et al. Neutrophils, as "Trojan horses", participate in the delivery of therapeutical PLGA nanoparticles into a tumor based on the chemotactic effect. Drug Deliv 2020; 27:1-14.

[163] Zarbock A, Ley K. Neutrophil adhesion and activation under flow. Microcirculation 2009; 16:31-42.

[164] Asaduzzaman M, Rahman M, Jeppsson B, Thorlacius H. P-selectin glycoprotein-ligand-1 regulates pulmonary recruitment of neutrophils in a platelet-independent manner in abdominal sepsis. Br J Pharmacol 2009; 156:307-15.

[165] Famta P, Shah S, Jain N, Srinivasarao DA, Vambhurkar G, Shahrukh S, et al. Nanocarrier-based drug delivery via cell-hitchhiking: emphasizing pharmacokinetic perspective towards taming the "big-old" tumors. J Drug Deliv Sci Technol 2023; 89:105050.

[166] Chu D, Dong X, Shi X, Zhang C, Wang Z. Neutrophil-based drug delivery systems. Adv Mater 2018; 30(22):1706245.

[167] Zhou L, Wu X, Qin S, Shi J, Yu C, Xu Z, et al. Cell-liposome delivery system based on neuroinflammation to target the amygdala for ameliorating depressive-like behaviors. Int J Pharm 2023; 637:122724.

[168] Kim SD, Lee HY, Shim JW, Kim HJ, Yoo YH, Park JS, et al. Activation of CXCR2 by extracellular matrix degradation product acetylated Pro-Gly-Pro has therapeutic effects against sepsis. Am J Respir Crit Care Med 2011; 184:243-51.

[169] Chen B, Luo M, Liang J, Zhang C, Gao C, Wang J, et al. Surface modification of PGP for a neutrophil-nanoparticle co-vehicle to enhance the anti-depressant effect of baicalein. Acta Pharm Sin B 2018; 8:64-73.

[170] Zhang C, Ling C, Pang L, Wang Q, Liu J, Wang B, et al. Direct macromolecular drug delivery to cerebral ischemia area using neutrophil-mediated nanoparticles. Theranostics 2017; 7:3260-75.

[171] Aguliar-Valles A, Kim J, Jung S, Woodside B, Luheshi GN. Role of brain transmigrating neutrophils in depression-like behavior during systemic infection. Mol Psychiatry 2014; 19:599-606.

[172] Quan X, Liang X, Ding Y, Han Y, Li J, Yuan M, et al. Cryo-shocked platelet coupled with ROS-responsive nanomedicine for targeted treatment of thromboembolic disease. ACS Nano 2023; 17:6519-33.

[173] Li Y, Teng X, Wang Y, Yang C, Yan X, Li J. Neutrophil delivered hollow titania covered persistent luminescent nanosensitizer for ultrosound augmented chemo/immuno glioblastoma therapy. Adv Sci 2021; 8:2004381.

[174] Lu L, Qi S, Chen Y, Luo H, Huang S, Yu X, et al. Targeted immunomodulation of inflammatory monocytes across the blood-brain barrier by curcumin-loaded nanoparticles delays the progression of experimental autoimmune encephalomyelitis. Biomaterials 2020; 245:119987.

[175] Wang L, Zhang Y, Ma Y, Zhai Y, Ji J, Yang X, et al. Cellular drug delivery system for disease treatment. Int J Pharm 2023; 641:123069.

[176] Hao M, Xia H, Duan J, Zhou H, Zhang G, Li D, et al. A living material constructed from stem cells for tumor-tropic oncotherapy with real-time imaging. Adv Funct Mater 2022; 32(24):2201013.

[177] Li QR, Xu HZ, Xiao RC, Liu Y, Tang JM, Li J, et al. Platelets are highly efficient and efficacious carriers for tumor-targeted nano-drug delivery. Drug Deliv 2022; 29:937-49.